Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors

By Kalmadi S.   Davis M.   Dowlati A.   O’Keefe S.   Cline-Burkhardt M.   Pelley R.   Borden E.   Dreicer R.   Bukowski R.   Mekhail T.  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis

By Garcia Agustin   Iqbal Syma   Quinn David   Edwards Susan   Lenz Heinz   Weber Jeff  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 79-83

Springer Publishing Company

Access to resources Recommend Favorite

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

By Dent S.   Gelmon K.   Chi K.   Jonker D.   Wainman N.   Capier C.   Chen E.   Lyons J.   Seymour L.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1522-1529

Springer Publishing Company

Access to resources Recommend Favorite

Predicting the Toxicity of Weekly Docetaxel in Advanced Cancer

By Charles Kellie A.  

Clinical Pharmacokinetics, Vol. 45, Iss. 6, 2006-01 ,pp. : 611-622

Adis International

Access to resources Recommend Favorite

A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

By Eder Jr Joseph P.   Garcia-Carbonero Rocio   Clark Jeffrey W.   Supko Jeffrey G.   Puchalski Thomas A.   Ryan David P.   Deluca Pamela   Wozniak Antoinette   Campbell Angela   Rothermel John   LoRusso Patricia  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 139-150

Springer Publishing Company

Access to resources Recommend Favorite